The Competition and Markets Authority has decided against investigating medicine stock shortages in the UK. It says it has other priorities and there is not enough persuasive evidence to justify an investigation. It claimed it was not the best-placed organisation to carry out an investigation even if one was needed. The CMA had found little evidence that the direct-to-pharmacy distribution model has contributed significantly to shortages. Parallel exporting out of the UK was also now less likely to lead to shortages due to a strengthening of the pound and the impact of quotas imposed by manufacturers. The CMA left open the possibility that it may investigate in the future if its priorities change.